Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Risk of Developing Hypokalemia in Patients With Hypertension Treated With Combination Antihypertensive Therapy

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Association of Fatal and Nonfatal Cardiovascular Outcomes With 24-Hour Mean Arterial Pressure

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Antihypertensive Drugs and Risk of Depression: A Nationwide Population-Based Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Does Estimated Pulse Wave Velocity Add Prognostic Information? MORGAM Prospective Cohort Project

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Level of Physical Activity, Left Ventricular Mass, Hypertension, and Prognosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Dose-Response Association Between Level of Physical Activity and Mortality in Normal, Elevated, and High Blood Pressure

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Maria Lukács Krogager
  • Rikke Nørmark Mortensen
  • Peter Enemark Lund
  • Henrik Bøggild
  • Steen Møller Hansen
  • Kristian Kragholm
  • Kristian Aasbjerg
  • Peter Søgaard
  • Christian Torp-Pedersen
View graph of relations

Little is known about the occurrence of hypokalemia due to combination therapy for hypertension. Using data from Danish administrative registries, we investigated the association between different combinations of antihypertensive therapy and risk of developing hypokalemia. Using incidence density matching, 2 patients without hypokalemia were matched to a patient with hypokalemia (K, <3.5 mmol/L) on age, sex, renal function, and time between index date and date of potassium measurement. Combination therapies were subdivided into 10 groups including β-blockers (BB)+thiazides (BB+thiazides), calcium channel blockers (CCB)+renin angiotensin system inhibitors (RASi)+thiazides (CCB+RASi+Thiazides), calcium channel blockers+thiazides (CCB+thiazides), and β-blockers+renin angiotensin system inhibitors+thiazides (BB+RASi+thiazides). We used conditional logistic regression to estimate the odds of developing hypokalemia for different combinations of antihypertensive drugs within 90 days of combination therapy initiation. We matched 463 patients with hypokalemia to 926 patients with normal potassium concentrations. The multivariable analysis showed 5.82× increased odds of developing hypokalemia if administered CCB+thiazides (95% CI, 3.06-11.08) compared with CCB+RASi. Other combinations significantly associated with increased hypokalemia odds were BB+thiazides (odds ratio, 3.34 [95% CI, 1.67-6.66]), CCB+RASi+thiazides (odds ratio, 3.07 [95% CI, 1.72-5.46]), and BB+RASi+thiazides (odds ratio, 2.78 [95% CI, 1.41-5.47]). Combinations of thiazides with CCB, RASi, or BB were strongly associated with increased hypokalemia risk within 90 days of treatment initiation.

Original languageEnglish
JournalHypertension
Volume75
Issue number4
Pages (from-to)966-972
Number of pages7
ISSN0194-911X
DOIs
Publication statusPublished - Apr 2020

ID: 59517779